Entrada Therapeutics, Inc. (TRDA) stock
TRDANasdaqPharmaceutical PreparationsFiscal year ends December 31
$5.17−0.27 (-4.96%)
Close on Nov 12, 2026Market cap $201.30MP/E –Yield –
Earnings
Entrada Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Feb 25, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
$900.00K
-43.8% on a year earlier
EPS, Q3 FY2026
-$0.94
-$1.06 a year earlier
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Entrada Therapeutics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 25, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $900.00K | -43.8% | -$0.94 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026before the open | $900.00K | -55.0% | -$1.01 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 7, 2026before the open | $900.00K | -95.6% | -$0.95 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 26, 2026before the open | $1.30M | -96.5% | -$0.94 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 6, 2025before the open | $1.60M | -91.8% | -$1.06 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 6, 2025before the open | $2.00M | -97.9% | -$1.04 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025before the open | $20.60M | -65.1% | -$0.42 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025before the open | $37.40M | -10.5% | $0.03 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 5, 2024before the open | $19.60M | -55.1% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 13, 2024before the open | $94.70M | +420.3% | $1.55 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024before the open | $59.10M | +133.6% | $0.68 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 13, 2024before the open | $41.80M | – | -$0.29 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023before the open | $43.70M | – | $1.02 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 8, 2023before the open | $18.20M | – | -$0.78 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 10, 2023before the open | $25.30M | – | -$0.21 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 6, 2023before the open | – | – | -$0.79 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 7, 2022before the open | – | – | -$0.80 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 12, 2022before the open | – | – | -$0.69 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 15, 2022before the open | – | – | -$0.89 | Release |
| Q3 FY2021ended Sep 30, 2021 | Dec 9, 2021before the open | – | – | -$9.78 | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Entrada Therapeutics has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Entrada Therapeutics puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Entrada Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Update
See a number that looks wrong?